Details of the Drug

General Information of Drug (ID: DMSC4A7)

Drug Name
Indomethacin
Synonyms
Aconip; Amuno; Arthrexin; Artracin; Artrinovo; Artrivia; Bonidin; Bonidon; Catlep; Confortid; Dolcidium; Dolovin; Durametacin; Elmetacin; Hicin; IMN; Idomethine; Imbrilon; Inacid; Indacin; Indameth; Indmethacine; Indocid; Indocin; Indomecol; Indomed; Indomee; Indometacin; Indometacina; Indometacine; Indometacinum; Indometacyna; Indomethacine; Indomethacinum; Indomethancin; Indomethazine; Indomethegan; Indomethine; Indometicina; Indomo; Indomod; Indoptic; Indoptol; Indorektal; Indoxen; Inflazon; Infrocin; Lausit; Liometacen; Metacen; Metartril; Methazine; Metindol; Mezolin; Miametan; Mikametan; Mobilan; Novomethacin; Reumacide; Sadoreum; Tannex; Vonum; Bonidon Gel; DESMETHYL INDOMETHACIN; Dolcidium PL;Flexin continus; Indocid Pda; Indocid Sr; Indocin Sr; Indolar SR; Indometacyna [Polish]; Indometicina [Spanish]; Inteban sp; Rhemacin LA; Rheumacin LA; I 7378; IN1454; Indomet 140; Aconip (TN); Apo-Indomethacin; Chibro-amuno; Chrono-indicid; Chrono-indocid; Indo-Lemmon; Indo-Spray; Indo-phlogont; Indo-rectolmin; Indo-tablinen; Indocid (TN); Indocid (pharmaceutical); Indocin (TN); Indocin I.V; Indometacina [INN-Spanish]; Indometacine [INN-French]; Indometacinum [INN-Latin]; Indomethacin (USP); Indomethacin [USAN:BAN]; Novo-Methacin; Indochron E-R (TN); Indocin I.V.; Indocin-SR (TN); Indometacin (JP15/INN); Indomethacin & MAP-30; Indomethacin, Indochron E-R, Indocin-SR, Indocid, Indocin, Indomethacin
Indication
Disease Entry ICD 11 Status REF
Bursitis N.A. Approved [1]
Gout FA25 Approved [1]
Osteoarthritis FA00-FA05 Approved [1]
Patent ductus arteriosus N.A. Approved [1]
Rheumatic disorder N.A. Approved [1]
Rheumatoid arthritis FA20 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 1/2 [3]
Synovitis N.A. Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Antiinflammatory Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 357.8
Logarithm of the Partition Coefficient (xlogp) 4.3
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability
99% of drug becomes completely available to its intended biological destination(s) [5]
Clearance
The drug present in the plasma can be removed from the body at the rate of 1.3 mL/min/kg [6]
Elimination
15% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.4 hours [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 7.985 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.01% [6]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.096 L/kg [6]
Water Solubility
The ability of drug to dissolve in water is measured as 0.0025 mg/mL [4]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Apoptosis Not Available MYB OTJH64IV [8]
Cytology abnormal Not Available HRAS OTFYE6AJ [8]
Enterocolitis Not Available KLKB1 OTGSEISX [8]
Enterocolitis Not Available BDKRB2 OTOA9D3W [8]
Gastric disorder Not Available TNFRSF1A OT2D9DOV [8]
Gastric disorder Not Available ICAM1 OTTOIX77 [8]
Gastric disorder Not Available SELP OTWR90PK [8]
Injury Not Available ACHE OT2H8HG6 [8]
Metabolic disorder Not Available CYB5A OT6SN4RM [8]
Metabolic disorder Not Available EPHX1 OTBKWQER [8]
Metabolic disorder Not Available HSPA12A OTFOCDD6 [8]
Metabolic disorder Not Available CYB5R3 OTUGT3G8 [8]
⏷ Show the Full List of 12 ADR Information of This Drug
Chemical Identifiers
Formula
C19H16ClNO4
IUPAC Name
2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid
Canonical SMILES
CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O
InChI
InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)
InChIKey
CGIGDMFJXJATDK-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3715
ChEBI ID
CHEBI:49662
CAS Number
53-86-1
DrugBank ID
DB00328
TTD ID
D0R1RS
VARIDT ID
DR00267
INTEDE ID
DR0875
ACDINA ID
D00329
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Modulator [9]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [11]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [11]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [11]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [12]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [12]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) OTHF4H9U DHI2_HUMAN Gene/Protein Processing [13]
14-3-3 protein epsilon OT3WQXNA 1433E_HUMAN Gene/Protein Processing [14]
15-hydroxyprostaglandin dehydrogenase (HPGD) OTYZI6JB PGDH_HUMAN Gene/Protein Processing [15]
5'-nucleotidase (NT5E) OT7J5LT6 5NTD_HUMAN Gene/Protein Processing [16]
A disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS1) OTTLJH8W ATS1_HUMAN Gene/Protein Processing [17]
ABC-type organic anion transporter ABCA8 (ABCA8) OTCWLX6N ABCA8_HUMAN Gene/Protein Processing [18]
Acetyl-CoA carboxylase 1 (ACACA) OT5CQPZY ACACA_HUMAN Gene/Protein Processing [19]
Acetylcholinesterase (ACHE) OT2H8HG6 ACES_HUMAN Drug Response [8]
Acrosin-binding protein (ACRBP) OT0MK3L1 ACRBP_HUMAN Gene/Protein Processing [17]
Activity-dependent neuroprotector homeobox protein (ADNP) OTEGICWR ADNP_HUMAN Gene/Protein Processing [17]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Bursitis
ICD Disease Classification
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin G/H synthase 2 (COX-2) DTT PTGS2 2.03E-07 1.68 3.86
P-glycoprotein 1 (ABCB1) DTP P-GP 2.16E-04 -1.07E+00 -2.77E+00
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 1.87E-02 -4.28E-01 -1.94E+00
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 5.51E-02 1.95E-01 1.20E+00
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 3.04E-01 -5.14E-02 -1.57E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Indomethacin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Sulfasalazine DMICA9H Moderate Increased risk of nephrotoxicity by the combination of Indomethacin and Sulfasalazine. Rheumatoid arthritis [FA20] [20]
Dexamethasone DMMWZET Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Dexamethasone. Rheumatoid arthritis [FA20] [21]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Indomethacin and Leflunomide. Rheumatoid arthritis [FA20] [22]
Coadministration of a Drug Treating the Disease Different from Indomethacin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Indomethacin and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [23]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Indomethacin and Repaglinide. Acute diabete complication [5A2Y] [24]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Indomethacin and Glibenclamide. Acute diabete complication [5A2Y] [24]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Indomethacin and Tolazamide. Acute diabete complication [5A2Y] [24]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Indomethacin and Nateglinide. Acute diabete complication [5A2Y] [24]
Acetohexamide DMR6N7H Moderate Increased risk of hypoglycemia by the combination of Indomethacin and Acetohexamide. Acute diabete complication [5A2Y] [24]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Indomethacin and Glipizide. Acute diabete complication [5A2Y] [24]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of Indomethacin and Thioguanine. Acute myeloid leukaemia [2A60] [25]
Arn-509 DMT81LZ Moderate Accelerated clearance of Indomethacin due to the transporter induction by Arn-509. Acute myeloid leukaemia [2A60] [26]
Inotersen DMJ93CT Major Increased risk of bleeding by the combination of Indomethacin and Inotersen. Amyloidosis [5D00] [26]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Indomethacin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [27]
Cilostazol DMZMSCT Moderate Increased risk of bleeding by the combination of Indomethacin and Cilostazol. Arterial occlusive disease [BD40] [28]
Voriconazole DMAOL2S Moderate Decreased metabolism of Indomethacin caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [23]
Budesonide DMJIBAW Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Budesonide. Asthma [CA23] [21]
Ofloxacin DM0VQN3 Moderate Additive CNS depression effects by the combination of Indomethacin and Ofloxacin. Bacterial infection [1A00-1C4Z] [29]
Kanamycin DM2DMPO Moderate Increased risk of nephrotoxicity by the combination of Indomethacin and Kanamycin. Bacterial infection [1A00-1C4Z] [30]
Ciprofloxacin XR DM2NLS9 Moderate Additive CNS depression effects by the combination of Indomethacin and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [29]
Amikacin DM5PDRB Moderate Increased risk of nephrotoxicity by the combination of Indomethacin and Amikacin. Bacterial infection [1A00-1C4Z] [30]
Trovafloxacin DM6AN32 Moderate Additive CNS depression effects by the combination of Indomethacin and Trovafloxacin. Bacterial infection [1A00-1C4Z] [29]
Sparfloxacin DMB4HCT Moderate Additive CNS depression effects by the combination of Indomethacin and Sparfloxacin. Bacterial infection [1A00-1C4Z] [29]
Streptomycin DME1LQN Moderate Increased risk of nephrotoxicity by the combination of Indomethacin and Streptomycin. Bacterial infection [1A00-1C4Z] [30]
Gemifloxacin DMHT34O Moderate Additive CNS depression effects by the combination of Indomethacin and Gemifloxacin. Bacterial infection [1A00-1C4Z] [29]
Norfloxacin DMIZ6W2 Moderate Additive CNS depression effects by the combination of Indomethacin and Norfloxacin. Bacterial infection [1A00-1C4Z] [29]
ABT-492 DMJFD2I Moderate Additive CNS depression effects by the combination of Indomethacin and ABT-492. Bacterial infection [1A00-1C4Z] [29]
Gentamicin DMKINJO Moderate Increased risk of nephrotoxicity by the combination of Indomethacin and Gentamicin. Bacterial infection [1A00-1C4Z] [30]
Netilmicin DMRD1QK Moderate Increased risk of nephrotoxicity by the combination of Indomethacin and Netilmicin. Bacterial infection [1A00-1C4Z] [30]
Levofloxacin DMS60RB Moderate Additive CNS depression effects by the combination of Indomethacin and Levofloxacin. Bacterial infection [1A00-1C4Z] [29]
Tobramycin DMUI0CH Moderate Increased risk of nephrotoxicity by the combination of Indomethacin and Tobramycin. Bacterial infection [1A00-1C4Z] [30]
Lomefloxacin DMVRH9C Moderate Additive CNS depression effects by the combination of Indomethacin and Lomefloxacin. Bacterial infection [1A00-1C4Z] [29]
Etidronic acid DM1XHYJ Moderate Increased risk of nephrotoxicity by the combination of Indomethacin and Etidronic acid. Bone paget disease [FB85] [31]
Risedronate DM5FLTY Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Risedronate. Bone paget disease [FB85] [31]
Alendronate DMY2KX9 Moderate Increased risk of nephrotoxicity by the combination of Indomethacin and Alendronate. Bone paget disease [FB85] [31]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Indomethacin and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [32]
Alpelisib DMEXMYK Moderate Increased metabolism of Indomethacin caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [33]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of bleeding by the combination of Indomethacin and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [28]
Grepafloxacin DMGLX0T Moderate Additive CNS depression effects by the combination of Indomethacin and Grepafloxacin. Bronchitis [CA20] [29]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Indomethacin and Iodipamide. Cholelithiasis [DC11] [34]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Indomethacin and Levomilnacipran. Chronic pain [MG30] [35]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Indomethacin and Regorafenib. Colorectal cancer [2B91] [26]
Oxaliplatin DMQNWRD Moderate Decreased renal excretion of Indomethacin caused by Oxaliplatin mediated nephrotoxicity. Colorectal cancer [2B91] [36]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Indomethacin and Drospirenone. Contraceptive management [QA21] [37]
Methoxyflurane DML0RAE Moderate Increased risk of nephrotoxicity by the combination of Indomethacin and Methoxyflurane. Corneal disease [9A76-9A78] [26]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Indomethacin and Ardeparin. Coronary thrombosis [BA43] [38]
Mifepristone DMGZQEF Moderate Decreased metabolism of Indomethacin caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [39]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Indomethacin caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [40]
Cidofovir DMA13GD Major Increased risk of nephrotoxicity by the combination of Indomethacin and Cidofovir. Cytomegaloviral disease [1D82] [41]
MK-8228 DMOB58Q Moderate Increased metabolism of Indomethacin caused by MK-8228 mediated induction of CYP450 enzyme. Cytomegaloviral disease [1D82] [42]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Indomethacin and Danaparoid. Deep vein thrombosis [BD71] [38]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Indomethacin and Rivaroxaban. Deep vein thrombosis [BD71] [43]
Aprepitant DM053KT Moderate Increased metabolism of Indomethacin caused by Aprepitant mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [44]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Indomethacin and Sertraline. Depression [6A70-6A7Z] [35]
Fluoxetine DM3PD2C Moderate Increased risk of bleeding by the combination of Indomethacin and Fluoxetine. Depression [6A70-6A7Z] [35]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Indomethacin and Vilazodone. Depression [6A70-6A7Z] [35]
Paroxetine DM5PVQE Moderate Increased risk of bleeding by the combination of Indomethacin and Paroxetine. Depression [6A70-6A7Z] [35]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Indomethacin and Vortioxetine. Depression [6A70-6A7Z] [35]
Duloxetine DM9BI7M Moderate Increased risk of bleeding by the combination of Indomethacin and Duloxetine. Depression [6A70-6A7Z] [35]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Indomethacin and Milnacipran. Depression [6A70-6A7Z] [35]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Indomethacin and Escitalopram. Depression [6A70-6A7Z] [35]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Indomethacin and Desvenlafaxine. Depression [6A70-6A7Z] [35]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Indomethacin and Clomipramine. Depression [6A70-6A7Z] [35]
PMID28870136-Compound-49 DMTUC9E Moderate Increased risk of bleeding by the combination of Indomethacin and PMID28870136-Compound-49. Discovery agent [N.A.] [45]
Fenfluramine DM0762O Moderate Increased risk of bleeding by the combination of Indomethacin and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [35]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Indomethacin and Cannabidiol. Epileptic encephalopathy [8A62] [26]
Ethacrynic acid DM60QMR Moderate Antagonize the effect of Indomethacin when combined with Ethacrynic acid. Essential hypertension [BA00] [46]
Bendroflumethiazide DM7EVLC Moderate Antagonize the effect of Indomethacin when combined with Bendroflumethiazide. Essential hypertension [BA00] [46]
Benzthiazide DMQWZ0H Moderate Antagonize the effect of Indomethacin when combined with Benzthiazide. Essential hypertension [BA00] [46]
Tazemetostat DMWP1BH Moderate Increased risk of bleeding by the combination of Indomethacin and Tazemetostat. Follicular lymphoma [2A80] [28]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Indomethacin and Avapritinib. Gastrointestinal stromal tumour [2B5B] [26]
Sulfinpyrazone DMEV954 Moderate Increased risk of bleeding by the combination of Indomethacin and Sulfinpyrazone. Gout [FA25] [28]
Spironolactone DM2AQ5N Moderate Antagonize the effect of Indomethacin when combined with Spironolactone. Heart failure [BD10-BD1Z] [46]
Triamterene DM2HU9I Moderate Antagonize the effect of Indomethacin when combined with Triamterene. Heart failure [BD10-BD1Z] [46]
Eplerenone DMF0NQR Moderate Increased risk of hyperkalemia by the combination of Indomethacin and Eplerenone. Heart failure [BD10-BD1Z] [47]
Chlorothiazide DMLHESP Moderate Antagonize the effect of Indomethacin when combined with Chlorothiazide. Heart failure [BD10-BD1Z] [46]
Furosemide DMMQ8ZG Moderate Antagonize the effect of Indomethacin when combined with Furosemide. Heart failure [BD10-BD1Z] [46]
Amiloride DMRTSGP Moderate Antagonize the effect of Indomethacin when combined with Amiloride. Heart failure [BD10-BD1Z] [46]
Bumetanide DMRV7H0 Moderate Antagonize the effect of Indomethacin when combined with Bumetanide. Heart failure [BD10-BD1Z] [46]
Hydroflumethiazide DMVPUQI Moderate Antagonize the effect of Indomethacin when combined with Hydroflumethiazide. Heart failure [BD10-BD1Z] [46]
Rifapentine DMCHV4I Moderate Increased metabolism of Indomethacin caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [48]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Indomethacin and Brentuximab vedotin. Hodgkin lymphoma [2B30] [49]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Indomethacin and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [50]
Etravirine DMGV8QU Moderate Decreased metabolism of Indomethacin caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [51]
Ritonavir DMU764S Minor Increased metabolism of Indomethacin caused by Ritonavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [52]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Indomethacin caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [23]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Indomethacin and Mipomersen. Hyper-lipoproteinaemia [5C80] [53]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Indomethacin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [22]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Indomethacin and BMS-201038. Hyper-lipoproteinaemia [5C80] [54]
Indapamide DMGN1PW Moderate Antagonize the effect of Indomethacin when combined with Indapamide. Hypertension [BA00-BA04] [46]
Trichlormethiazide DMHAQCO Moderate Antagonize the effect of Indomethacin when combined with Trichlormethiazide. Hypertension [BA00-BA04] [46]
Hydrochlorothiazide DMUSZHD Moderate Antagonize the effect of Indomethacin when combined with Hydrochlorothiazide. Hypertension [BA00-BA04] [55]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of Indomethacin and Dipyridamole. Hypertension [BA00-BA04] [28]
Potassium chloride DMMTAJC Moderate Increased risk of hyperkalemia by the combination of Indomethacin and Potassium chloride. Hypo-kalaemia [5C77] [56]
Fludrocortisone DMUDIR8 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [21]
Balsalazide DM7I1T9 Moderate Increased risk of nephrotoxicity by the combination of Indomethacin and Balsalazide. Indeterminate colitis [DD72] [20]
Methotrexate DM2TEOL Major Increased risk of nephrotoxicity by the combination of Indomethacin and Methotrexate. Leukaemia [2A60-2B33] [57]
Ibandronate DM0QZBN Moderate Increased risk of nephrotoxicity by the combination of Indomethacin and Ibandronate. Low bone mass disorder [FB83] [26]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Indomethacin and Porfimer Sodium. Lung cancer [2C25] [58]
PF-06463922 DMKM7EW Moderate Increased metabolism of Indomethacin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [23]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Indomethacin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [59]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Indomethacin and Idelalisib. Mature B-cell leukaemia [2A82] [60]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Indomethacin and Acalabrutinib. Mature B-cell lymphoma [2A85] [61]
Clofarabine DMCVJ86 Moderate Increased risk of nephrotoxicity by the combination of Indomethacin and Clofarabine. Mature B-cell lymphoma [2A85] [26]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Indomethacin and Ibrutinib. Mature B-cell lymphoma [2A85] [62]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Indomethacin and Ponatinib. Mature B-cell lymphoma [2A85] [63]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Indomethacin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [26]
Nitisinone DMVS9WQ Moderate Decreased metabolism of Indomethacin caused by Nitisinone mediated inhibition of CYP450 enzyme. Metabolism inborn error [5C50] [45]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Indomethacin and Exjade. Mineral absorption/transport disorder [5C64] [64]
Zoledronate DMIXC7G Moderate Increased risk of nephrotoxicity by the combination of Indomethacin and Zoledronate. Mineral excesses [5B91] [26]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Indomethacin and Panobinostat. Multiple myeloma [2A83] [23]
Deflazacort DMV0RNS Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Deflazacort. Muscular dystrophy [8C70] [21]
Imatinib DM7RJXL Moderate Decreased metabolism of Indomethacin caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [65]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Indomethacin and Dasatinib. Myeloproliferative neoplasm [2A20] [66]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Indomethacin and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [67]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Indomethacin and Prasugrel. Myocardial infarction [BA41-BA43] [26]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Indomethacin and Vorapaxar. Myocardial infarction [BA41-BA43] [68]
Tirofiban DMQG17S Moderate Increased risk of bleeding by the combination of Indomethacin and Tirofiban. Myocardial infarction [BA41-BA43] [69]
Sibutramine DMFJTDI Moderate Increased risk of bleeding by the combination of Indomethacin and Sibutramine. Obesity [5B80-5B81] [35]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Indomethacin and Dexfenfluramine. Obesity [5B80-5B81] [35]
Metolazone DMB39LO Moderate Antagonize the effect of Indomethacin when combined with Metolazone. Oedema [MG29] [46]
Polythiazide DMCH80F Moderate Antagonize the effect of Indomethacin when combined with Polythiazide. Oedema [MG29] [46]
Diclofenac DMPIHLS Moderate Increased risk of hepatotoxicity by the combination of Indomethacin and Diclofenac. Osteoarthritis [FA00-FA05] [70]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Indomethacin caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [71]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Indomethacin and MK-4827. Ovarian cancer [2C73] [26]
Aspirin DM672AH Moderate Increased risk of bleeding by the combination of Indomethacin and Aspirin. Pain [MG30-MG3Z] [72]
Prednisone DM2HG4X Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Prednisone. Postoperative inflammation [1A00-CA43] [21]
Betamethasone DMAHJEF Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Betamethasone. Postoperative inflammation [1A00-CA43] [21]
Hydrocortisone DMGEMB7 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Hydrocortisone. Postoperative inflammation [1A00-CA43] [21]
Enzalutamide DMGL19D Moderate Increased metabolism of Indomethacin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [73]
Bosentan DMIOGBU Moderate Increased metabolism of Indomethacin caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [74]
Treprostinil DMTIQF3 Moderate Increased risk of bleeding by the combination of Indomethacin and Treprostinil. Pulmonary hypertension [BB01] [75]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Indomethacin and Epoprostenol. Pulmonary hypertension [BB01] [75]
Everolimus DM8X2EH Major Increased risk of nephrotoxicity by the combination of Indomethacin and Everolimus. Renal cell carcinoma [2C90] [76]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Indomethacin and Temsirolimus. Renal cell carcinoma [2C90] [76]
Gatifloxacin DMSL679 Moderate Additive CNS depression effects by the combination of Indomethacin and Gatifloxacin. Respiratory infection [CA07-CA4Z] [29]
Methylprednisolone DM4BDON Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [21]
Cyclophosphamide DM4O2Z7 Minor Increased risk of hyponatremia by the combination of Indomethacin and Cyclophosphamide. Solid tumour/cancer [2A00-2F9Z] [77]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Indomethacin and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [26]
Prednisolone DMQ8FR2 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [21]
Pitolisant DM8RFNJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Pitolisant. Somnolence [MG42] [26]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Indomethacin and Naltrexone. Substance abuse [6C40] [78]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of Indomethacin and Caplacizumab. Thrombocytopenia [3B64] [28]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Indomethacin and Apixaban. Thrombosis [DB61-GB90] [26]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Indomethacin and Cangrelor. Thrombosis [DB61-GB90] [28]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Indomethacin and Brilinta. Thrombosis [DB61-GB90] [26]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Indomethacin and Cabozantinib. Thyroid cancer [2D10] [79]
Sirolimus DMGW1ID Major Increased risk of nephrotoxicity by the combination of Indomethacin and Sirolimus. Transplant rejection [NE84] [76]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Indomethacin and Tacrolimus. Transplant rejection [NE84] [76]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Indomethacin and Tolbutamide. Type 2 diabetes mellitus [5A11] [24]
Chlorpropamide DMPHZQE Moderate Increased risk of hypoglycemia by the combination of Indomethacin and Chlorpropamide. Type 2 diabetes mellitus [5A11] [24]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Indomethacin and Olsalazine. Ulcerative colitis [DD71] [20]
Cinoxacin DM4EWNS Moderate Additive CNS depression effects by the combination of Indomethacin and Cinoxacin. Urinary tract infection [GC08] [29]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Indomethacin and Plazomicin. Urinary tract infection [GC08] [30]
Nalidixic acid DMRM0JV Moderate Additive CNS depression effects by the combination of Indomethacin and Nalidixic acid. Urinary tract infection [GC08] [29]
Enoxacin DMYTE6L Moderate Additive CNS depression effects by the combination of Indomethacin and Enoxacin. Urinary tract infection [GC08] [29]
Triamcinolone DM98IXF Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Triamcinolone. Vasomotor/allergic rhinitis [CA08] [21]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Indomethacin and Betrixaban. Venous thromboembolism [BD72] [80]
⏷ Show the Full List of 155 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Hydrazine yellow E00409 164825 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Ammonia E00007 222 Alkalizing agent
Butyl alcohol E00011 263 Flavoring agent; Solvent
Carboxymethylcellulose sodium E00621 Not Available Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Lithol rubin BCA E00607 135423095 Colorant
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
Water E00035 962 Solvent
⏷ Show the Full List of 34 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Indomethacin 25 mg capsule 25 mg Oral Capsule Oral
Indomethacin 50 mg capsule 50 mg Oral Capsule Oral
Indomethacin 20 mg capsule 20 mg Oral Capsule Oral
Indomethacin 75 mg capsule 75 mg Extended Release Oral Capsule Oral
Indomethacin 40 mg capsule 40 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Indomethacin FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 ClinicalTrials.gov (NCT04344457) Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19. U.S. National Institutes of Health.
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10 Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1. Br J Cancer. 2007 Oct 22;97(8):1077-83.
11 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
12 Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol. 2007 Mar;63(3):289-96.
13 Prostaglandins and leukotriene B4 are potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 2 activity in human choriocarcinoma JEG-3 cells. Biol Reprod. 1999 Jul;61(1):40-5.
14 Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon. Cancer Res. 2007 Apr 1;67(7):3185-91. doi: 10.1158/0008-5472.CAN-06-3431.
15 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells. Arch Biochem Biophys. 2009 Jul 15;487(2):139-45. doi: 10.1016/j.abb.2009.05.017. Epub 2009 Jun 6.
16 Indomethacin stimulates activity and expression of ecto-5'-nucleotidase/CD73 in glioma cell lines. Eur J Pharmacol. 2007 Aug 13;569(1-2):8-15.
17 Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells. Neoplasia. 2006 Sep;8(9):758-71.
18 Evaluation of developmental toxicity using undifferentiated human embryonic stem cells. J Appl Toxicol. 2015 Feb;35(2):205-18.
19 Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell Biol Toxicol. 2021 Apr;37(2):151-175. doi: 10.1007/s10565-020-09537-1. Epub 2020 Jun 14.
20 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
21 Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
22 EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
23 Cerner Multum, Inc. "Australian Product Information.".
24 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
25 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
26 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
27 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
28 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
29 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
30 Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
31 Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
32 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
33 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
34 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
35 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
36 Product Information. Eloxatin (oxaliplatin). Sanofi Winthrop Pharmaceuticals, New York, NY.
37 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
38 Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
39 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
40 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
41 Product Information. Vistide (cidofovir). Gilead Sciences, Foster City, CA.
42 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
43 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
44 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
45 Canadian Pharmacists Association.
46 Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
47 Abdel-Haq B, Magagna A, Favilla S, Salvetti A "Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects." J Cardiovasc Pharmacol 18 (1991): s33-6. [PMID: 1725198]
48 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
49 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
50 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
51 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
52 Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
53 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
54 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
55 McCarthy JT, Torres VE, Romero JC, et al "Acute intrinsic renal failure induced by indomethacin." Mayo Clin Proc 57 (1982): 289-96. [PMID: 6952058]
56 Product Information. Potassium Chloride ER (potassium chloride). Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.
57 Adams JD, Hunter GA "Drug interaction in psoriasis." Australas J Dermatol 17 (1976): 39-40. [PMID: 1022213]
58 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
59 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
60 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
61 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
62 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
63 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
64 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
65 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
66 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
67 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
68 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
69 Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
70 Product Information. Solaraze (diclofenac topical). Doak Dermatologics Division, Fairfield, NJ.
71 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
72 Concomitant use of ibuprofen and aspirin. J Pain Palliat Care Pharmacother 21 (2007): 73-4. [PMID: 17844731]
73 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
74 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
75 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
76 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
77 Webberley MJ, Murray JA "Life-threatening acute hyponatraemia induced by low dose cyclophosphamide and indomethacin." Postgrad Med J 65 (1989): 950-2. [PMID: 2616440]
78 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
79 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
80 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.